• Home
  • Repotrectinib 40mg
  • Repotrectinib 40mg

Repotrectinib 40mg

52162

Repotrectinib is used for adults with ROS1-positive non-small cell lung cancer that is locally advanced or has spread.

It is also used for adults and children aged 12 years and older with solid tumours that have an NTRK gene fusion when the tumour has spread or cannot be removed by surgery and there is no good alternative treatment.

Usual adult dose range: 80mg once daily to 160mg twice daily; treatment commonly starts at 160mg once daily for 14 days and then increases to 160mg twice daily if tolerated.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.